Ask AI

Myeloma Myth Busters: Investigating the Now, Soon, and Future Clinical Implications of CELMoD Agents

Enhance your knowledge of CELMoD agents by reviewing mechanistic aspects of these novel therapeutics and key clinical trial data across the disease continuum of multiple myeloma through a podcast, certified on-demand webcast, expert-written ClinicalThought commentary, and accompanying downloadable slides.

Share

Program Content

Activities

CELMoD Agent Trial Data in MM
CELMoD Agents in Maintenance and Early-Relapse Settings for Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 03, 2025

MRD in MM
MRD—Trial Endpoint or Clinical Tool in Multiple Myeloma?
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 04, 2025

CELMoD Agents for MM
The Why and How of CELMoD Agents for Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 04, 2025

Activities

Implications of CELMoDs in MM
Myeloma Myth Busters: Investigating the Now, Soon, and Future Clinical Implications of CELMoDs
Video
Congratulations: You achieved a completion on 04/09/2022

Released: December 29, 2025

Expires: June 28, 2026

Activities

CELMoD Agents in MM
Experts Answer Questions About CELMoD Agents in Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 30, 2025

Activities

CELMoD Agents in MM
Experts Discuss CELMoD Agents for Treating Multiple Myeloma
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 30, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb